Improved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials.

Jendle J, Birkenfeld AL, Polonsky WH, Silver R, Uusinarkaus K, Hansen T, Håkan-Bloch J, Tadayon S, Davies MJ

Diabetes, obesity & metabolism12 Jul 2019Cited by 17 (Europe PMC)

PMID31215727PMCIDPMC6771774DOI10.1111/dom.13816PepBankPUB-31215727

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, satisfaction improvements were generally greater in patients who reached weight loss and HbA1c targets, often with semaglutide 1.0 mg versus comparator or placebo.
In plain wordsIn adults with type 2 diabetes, satisfaction gains were generally larger in people who reached weight and blood sugar targets.
Peptide
Semaglutide
Outcome
IncreaseTreatment satisfaction by weight loss and glycaemic target achievement
Study
n: not reported in source
Comparator
Comparators or placebo
Analysis
Exploratory
Outcome group
Patient-reported outcomes · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
and generally greater in patients who achieved versus did not achieve weight loss and glycaemic targets, often with greater improvements with semaglutide 1.0 mg versus comparator/placebo in both weight loss groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Post hoc subgroup analyses were conducted to explore the effects of gastrointestinal adverse events (GI AEs), weight loss (≥5%) or achieving glycaemic (HbA1c < 7%) targets on treatment satisfaction.
Summary · context
In SUSTAIN 2-5 and 7, the Diabetes Treatment Satisfaction Questionnaire was used to evaluate patient-perceived treatment satisfaction, hyperglycaemia and hypoglycaemia.
Report a problemFND-3121572703
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes in SUSTAIN 2-5, treatment satisfaction improved more with semaglutide than with comparators or placebo.
In plain wordsIn adults with type 2 diabetes, treatment satisfaction rose more with semaglutide than with placebo or the comparison drugs.
Peptide
Semaglutide
Outcome
IncreaseOverall treatment satisfaction, SUSTAIN 2-5
Study
n: not reported in source
Comparator
Placebo or active comparators
Outcome group
Patient-reported outcomes · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Improvements were significantly greater with semaglutide versus comparators/placebo in SUSTAIN 2-5 (all P < 0.05)
1 context sentence(design, population, supporting numbers)
Summary · context
In SUSTAIN 2-5 and 7, the Diabetes Treatment Satisfaction Questionnaire was used to evaluate patient-perceived treatment satisfaction, hyperglycaemia and hypoglycaemia.
Report a problemFND-3121572701
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes in SUSTAIN 7, improvements in treatment satisfaction were generally similar between semaglutide and dulaglutide.
In plain wordsIn adults with type 2 diabetes, semaglutide and dulaglutide gave similar gains in treatment satisfaction.
Peptide
Semaglutide
Outcome
No significant changeOverall treatment satisfaction, SUSTAIN 7
Study
n: not reported in source
Comparator
Dulaglutide
Outcome group
Patient-reported outcomes · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
In SUSTAIN 7, improvements in overall treatment satisfaction were generally similar between semaglutide and dulaglutide, irrespective of weight loss or glycaemic control.
1 context sentence(design, population, supporting numbers)
Summary · context
In SUSTAIN 2-5 and 7, the Diabetes Treatment Satisfaction Questionnaire was used to evaluate patient-perceived treatment satisfaction, hyperglycaemia and hypoglycaemia.
Report a problemFND-3121572702
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, perceived hyperglycaemia fell more with semaglutide than with all comparators or placebo.
In plain wordsIn adults with type 2 diabetes, people on semaglutide felt less high blood sugar than those on comparators or placebo.
Peptide
Semaglutide
Outcome
DecreasePerceived hyperglycaemia
Study
n: not reported in source
Comparator
All comparators or placebo
Outcome group
Patient-reported outcomes · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Perceived hyperglycaemia was significantly reduced from baseline to end of treatment with semaglutide versus all comparators/placebo (all P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
In SUSTAIN 2-5 and 7, the Diabetes Treatment Satisfaction Questionnaire was used to evaluate patient-perceived treatment satisfaction, hyperglycaemia and hypoglycaemia.
Report a problemFND-3121572705
05HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, perceived hypoglycaemia did not differ between semaglutide and the comparators or placebo.
In plain wordsIn adults with type 2 diabetes, felt low blood sugar did not differ between semaglutide and comparators or placebo.
Peptide
Semaglutide
Outcome
No significant changePerceived hypoglycaemia
Study
n: not reported in source
Comparator
Comparators or placebo
Outcome group
Patient-reported outcomes · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
No differences between treatments were observed for perceived hypoglycaemia.
1 context sentence(design, population, supporting numbers)
Summary · context
In SUSTAIN 2-5 and 7, the Diabetes Treatment Satisfaction Questionnaire was used to evaluate patient-perceived treatment satisfaction, hyperglycaemia and hypoglycaemia.
Report a problemFND-3121572706

Studies that did not test the peptide alone1

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

06HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome
In SUSTAIN 7, changes in treatment satisfaction were generally lower in patients with gastrointestinal adverse events at week 16 (semaglutide and dulaglutide pooled) but similar by week 40.
In plain wordsIn adults with type 2 diabetes on semaglutide or dulaglutide, stomach side effects lowered satisfaction gains early, but not by week 40.
Peptide
Semaglutide
Outcome
DecreaseTreatment satisfaction in patients with versus without GI adverse events, SUSTAIN 7
Study
n: not reported in source
Comparator
Patients without GI adverse events
Analysis
Exploratory
Outcome group
Patient-reported outcomes · Metabolic and weight
Source sentences
Summary
In SUSTAIN 7, changes in overall treatment satisfaction score were generally lower in patients with versus without GI AEs at week 16 (except dulaglutide 0.75 mg), but similar by week 40.
1 context sentence(design, population, supporting numbers)
Summary · context
In SUSTAIN 2-5 and 7, the Diabetes Treatment Satisfaction Questionnaire was used to evaluate patient-perceived treatment satisfaction, hyperglycaemia and hypoglycaemia.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3121572704

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials5

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

5 trials · 5 completed · 5 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT02648204